Back to today’s briefing

Story perspectives

Taxpayer Dollars Wasted on Ineffective Kidney Cancer Trials

2/4/2025

36 8

Summary

Story summary

The National Cancer Institute (NCI) has invested over $3 million in cabozantinib trials, yet results show minimal benefits for kidney cancer patients. This expenditure burdens taxpayers and Medicare, while enriching Exelixis shareholders. Furthermore, NCI's support for foreign drug development raises serious questions about financial oversight and the effectiveness of these investments.

1 of 1

Story summary

The National Cancer Institute (NCI) has invested over $3 million in cabozantinib trials, yet results show minimal benefits for kidney cancer patients. This expenditure burdens taxpayers and Medicare, while enriching Exelixis shareholders. Furthermore, NCI's support for foreign drug development raises serious questions about financial oversight and the effectiveness of these investments.